07/12/12Amarin shares plunge on decision to hire own sales force for Vascepa launch
14/11/11Amarin to present positive results from two phase 3 studies of anti-triglyceride drug
26/09/11Amarin submits NDA for triglyceride-lowering AMR101 drug
18/04/11Amarin shares surge on phase III results of triglyceride-lowering drug
Recent Sector News
The healthcare-docused consumer products group could buy back up to 3.8% of its shares in issue.
Pressure BioSciences rose in morning trades after the medtech firm entered into a two-year collaboration with The Institute of Bioinformatics (IOB), which is based in Bangalore, India. Shares advanced 13% to $0.260 at 10:26 a.m. in New York.
Hot on the heels of Friday's significant announcement of strong backing from a Polish institutional investor that specialises in small caps, Pressure BioSciences has announced record revenues for the first half of 2015.
Shire has been talking to Baxalta’s shareholders over a possible US$30bn deal and reports suggest the British firm is encouraged by the process
The stock price has lost over 20% in the past 24 hours as ‘The New Yorker’ asked in an article published on July 27 whether the company could afford to maintain its production in the United States
Chinese and Swiss researchers see Pressure BioSciences’ PCT platform as essential in improving clinical management of diabetes
High pressure is emerging as a powerful tool for understanding protein structure and function delivering direct evidence of the different ways proteins can respond to pressure.
Investors interested in Amarin recently viewed
- Pressure BioSciences (OTCQB: PBIO) High pressure instruments for physical and biological sciences
- SomnoMed (ASX: SOM) .
- ValiRx (AIM: VAL) Developing technologies & products in oncology therapeutics & diagnostics
- Regeneus Limited (ASX: RGS) .
- African Medical Investments (AIM: AMEI) Capital Appreciation through Private Healthcare in Africa